Kallistratos et al., 1980 - Google Patents
Inhibition of benzo (a) pyrene carcinogenesis in rats with vitamin CKallistratos et al., 1980
- Document ID
- 3842017129756697243
- Author
- Kallistratos G
- Fasske E
- Publication year
- Publication venue
- Journal of cancer research and clinical oncology
External Links
Snippet
The sc injection of 10 mg benzo (a) pyrene dissolved in 1 ml tricaprylin induced in Wistar rats local malignant tumors, such as fibrosarcoma, rhabdomyosarcoma, and polymorph cell sarcoma. The growth of the tumors was relatively rapid, reaching weights of 140–155 g …
- 229930003268 Vitamin C 0 title abstract description 49
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kallistratos et al. | Inhibition of benzo (a) pyrene carcinogenesis in rats with vitamin C | |
| Luo et al. | Inhibitory effects of molybdenum on esophageal and forestomach carcinogenesis in rats | |
| Cameron et al. | Ascorbic acid and cancer: a review | |
| JP2024063227A (en) | Combination Therapy for the Treatment of Mastocytosis - Patent application | |
| Kleinerman et al. | Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum (II) | |
| Conney et al. | Inhibitory effects of tea and caffeine on UV-induced carcinogenesis: relationship to enhanced apoptosis and decreased tissue fat | |
| Goldin et al. | Estimation of the antileukemic potency of the antimetabolite aminopterin, administered alone and in combination with citrovorum factor or folic acid | |
| Meguid et al. | The early cancer anorexia paradigm: changes in plasma free tryptophan and feeding indexes | |
| ATE229809T1 (en) | USE OF COMPOUNDS CONTAINING MAGNESIUM FOR THE TREATMENT OR PROPHYLAXIS OF CANCER AND AUTOIMMUNE DISEASES | |
| Mirvish et al. | Effect of sodium ascorbate on tumor induction in rats treated with morpholine and sodium nitrite, and with nitrosomorpholine | |
| US6255291B1 (en) | Composition and method for treating cancer and immunological disorders resulting in chronic conditions | |
| KR20050088994A (en) | Antioxidative composition | |
| Dragani et al. | Enhancing effects of carbon tetrachloride in mouse hepatocarcinogenesis | |
| Abul-Hajj et al. | Failure of ascorbic acid to inhibit growth of transplantable and dimethylbenzanthracene induced rat mammary tumors | |
| JP4405796B2 (en) | Cancer treatment with Goe 6976 and related compounds | |
| Harstrick et al. | A phase I dose escalation trial of intravenous treosulfan in refractory cancer | |
| Lazan et al. | Inhibition of the R3327MAT-Lu prostatic tumor by diethylstilbestrol and 1, 2-bis (3, 5-dioxopiperazin-1-yl) propane | |
| CN110664807B (en) | A kind of pharmaceutical composition with synergistic anti-melanoma efficacy and application thereof | |
| US5955466A (en) | Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea | |
| Koide et al. | Tannic acid raises survival rate of mice bearing syngeneic tumors | |
| Popović et al. | Diclofenac and metformin synergistic dose dependent inhibition of hamster fibrosarcoma, rescued with mebendazole | |
| Margreth et al. | The effects of hepatotoxic agents and of liver growth on the urinary excretion of the N-hydroxy metabolite of 2-acetylaminofluorene by rats | |
| EP0392662B1 (en) | Use of complexes of tetrachloroplatinate with a diazo dye as antitumour agents | |
| Seidel et al. | Leukemia induction by methylnitrosourea (MNU) in selected mouse strains: Effects of MNU on hemopoietic stem cells, the immune system and natural killer cells | |
| Anisimov | Effect of melatonin on life span and longevity |